UroGen Pharma Stock Forecast

Stock Price Forecast

The 7 analysts that cover UroGen Pharma stock have a consensus rating of "Strong Buy" and an average price target of $29.29, which forecasts a 57.56% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $47.

Price Target: $29.29 (+57.56%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$29.29	$33	$47
Change	-83.86%	+57.56%	+77.51%	+152.82%

Analyst Ratings

The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	4	4	4	3
Buy	3	3	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33	Strong Buy	Maintains	$33	+77.51%	Mar 2, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33	Strong Buy	Maintains	$33	+77.51%	Jan 23, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33	Strong Buy	Maintains	$33	+77.51%	Jan 5, 2026
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $40	Strong Buy	Reiterates	$40	+115.17%	Oct 27, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $25	Strong Buy	Maintains	$25	+34.48%	Oct 27, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

240.84M

from 109.79M

119.37%

from 109.79M

Revenue Next Year

396.88M

from 240.84M

64.79%

from 240.84M

EPS This Year

-1.20

from -3.19

EPS Next Year

0.77

from -1.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	48.04M	64.36M	82.71M	90.40M	109.79M	240.84M	396.88M
Revenue Growth	307.17%	33.96%	28.52%	9.29%	21.45%	119.37%	64.79%
EPS	-4.96	-4.81	-3.55	-2.96	-3.19	-1.20	0.77
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	24.17
No. Analysts	-	-	-	-	-	10	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	298.2M	601.2M
Avg	240.8M	396.9M
Low	187.3M	294.1M

Revenue Growth

Revenue Growth	2026	2027
High	171.6%	149.6%
Avg	119.4%	64.8%
Low	70.6%	22.1%

EPS Forecast

EPS	2026	2027
High	-0.57	1.65
Avg	-1.20	0.77
Low	-1.67	-0.17

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.